C5 and paroxysmal nocturnal hemoglobinuria: In the ALPHA phase II trial interim analysis, positive high-level results were found in PNH patients who exhibited significant clinical extravascular hemolysis when danicopan was added to the C5 inhibitor treatment of eculizumab or ravulizumab [102].